Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

Inhaled mRNA therapy for treatment of cystic fibrosis: Interim results of a randomized, double‐blind, placebo‐controlled phase 1/2 clinical study

Journal of Cystic Fibrosis(2023)10.1016/j.jcf.2023.04.008Source: DataRank Database

Inhaled mRNA therapy for treatment of cystic fibrosis: Interim results of a randomized, double‐blind, placebo‐controlled phase 1/2 clinical study is a research paper published in Journal of Cystic Fibrosis (2023). On theSindex it has a DataRank of 0. It has been cited 144 times.

N/A

0DataRank · unranked

Scored on demand from live citation data

Open Access144 citations

Download PDF

Cite:

Linked data & code

nct

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (3 grants)Impact (FWCI 24.44)OA: bronzeTopics (35)IDs (PubMed, PMC, OpenAlex)Annotations (1)SDGs (1)

FAIR Checklist

Context only (not used in score)

Findable (1/2)

Has DOI

Accessible (1/2)

Open Access

Interoperable (0/2)

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

Authors (20)

Jonathan B. Zuckerman ORCID,Daniel Dorgan ORCID,Jorge Lascano ORCID,Karen McCoy ORCID,Manu Jain ORCID

Live enrichment

PubMed:37121795 PMC:PMC10524666 OpenAlex:https://openalex.org/W4367396122

National Institutes of Health

Grant: P30DK072482

NCATS NIH HHS

Grant: UL1 TR002369

Cystic Fibrosis Foundation

FWCI

24.44

Citation Percentile

1.0%

Citation Trend

2023

2024

2025

2026

bronzeLicense: http://www.elsevier.com/open-access/userlicense/1.0/

journalhttp://www.cysticfibrosisjournal.com/article/S1569199323001121/pdf

publisherhttp://www.cysticfibrosisjournal.com/article/S1569199323001121/pdf

publisherhttps://api.elsevier.com/content/article/PII:S1569199323001121?httpAccept=text/xml

publisherhttps://api.elsevier.com/content/article/PII:S1569199323001121?httpAccept=text/plain

journalhttps://doi.org/10.1016/j.jcf.2023.04.008

Fields of Study

Cystic Fibrosis Research AdvancesRNA Interference and Gene DeliveryInhalation and Respiratory Drug DeliveryAdultHumansCystic FibrosisCystic Fibrosis Transmembrane Conductance RegulatorRNA, MessengerRespiratory Aerosols and DropletsMutationDouble-Blind Method

MeSH Terms

Respiratory Aerosols and DropletsAdultCystic FibrosisDouble-Blind MethodHumansMutationRNA, MessengerCystic Fibrosis Transmembrane Conductance Regulator

Keywords

MedicinePlaceboCohortAdverse effectCystic fibrosisDosingInternal medicineRandomized controlled trialPlacebo-controlled studyGastroenterologyAnesthesiaDouble blindPathologyGene therapyAerosolMrna Therapy

Sustainable Development Goals

SDG 0: Good health and well-being

Inhaled mRNA therapy for treatment of cystic fibrosis: Interim results of a randomized, double‐blind, placebo‐controlled phase 1/2 clinical study

FAIR Checklist

Authors (20)

Funding (3 grants)

Impact

Open Access

Topics

Annotations (Europe PMC)